Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy

  • J. Macías
  • M. M. Viloria
  • A. Rivero
  • I. de los Santos
  • M. Márquez
  • J. Portilla
  • F. Di Lello
  • A. Camacho
  • J. Sanz-Sanz
  • G. Ojeda
  • R. Mata
  • J. Gómez-Mateos
  • J. A. Pineda
  • on behalf of the FIBROCEL study group
Article

DOI: 10.1007/s10096-012-1546-5

Cite this article as:
Macías, J., Viloria, M.M., Rivero, A. et al. Eur J Clin Microbiol Infect Dis (2012) 31: 2083. doi:10.1007/s10096-012-1546-5

Abstract

The aim of this study was to analyze serum changes in mediators of fibrogenesis and in non-invasive markers of liver fibrosis among HIV/HCV-coinfected patients starting maraviroc (MVC)-based antiretroviral therapy. Patients included in this prospective pilot study met the following criteria: (1) HIV-infection, (2) detectable serum HCV-RNA, and ((3) started MVC. Transforming growth factor-β1 (TGF-beta1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were measured in serum samples at baseline and 6 months after starting MVC. AST-to-platelet ratio index (APRI) was assessed at the same time points. Twenty-four patients were analyzed. Median (IQR) serum levels at baseline and after 6 months on MVC of TGF-beta1 were 27,295 (20,562–36,844) and 33,753 (18,973–46,130) pg/mL (p = 0.116), of MMP-2 were 216 (186–274) and 241 (194–306) ng/mL (p = 0.247), and of TIMP-1 were 237 (170–284) and 216 (171–271) ng/mL (p = 0.415). APRI levels were 0.99 (0.53–3.46) at baseline and 0.83 (0.48–2.34) at 6 months (p = 0.16). Serum mediators of liver fibrogenesis and fibrosis do not change significantly in HIV/HCV-coinfected patients in the short-term after starting MVC. As TGF-beta1 levels have been shown to increase over time in HCV infection and liver fibrosis worsens rapidly in HIV/HCV coinfection, these parameters seem to evolve in a different way in MVC-treated patients.

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • J. Macías
    • 1
  • M. M. Viloria
    • 2
  • A. Rivero
    • 3
  • I. de los Santos
    • 4
  • M. Márquez
    • 5
  • J. Portilla
    • 6
  • F. Di Lello
    • 1
  • A. Camacho
    • 3
  • J. Sanz-Sanz
    • 4
  • G. Ojeda
    • 5
  • R. Mata
    • 1
  • J. Gómez-Mateos
    • 1
  • J. A. Pineda
    • 1
  • on behalf of the FIBROCEL study group
  1. 1.Unidad de Enfermedades Infecciosas y MicrobiologíaHospital Universitario de ValmeSevilleSpain
  2. 2.Servicio de BioquímicaHospital Universitario de ValmeSevilleSpain
  3. 3.Unidad de Enfermedades InfecciosasHospital Universitario de Reina SofíaCordobaSpain
  4. 4.Unidad de Enfermedades InfecciosasHospital Universitario la PrincesaMadridSpain
  5. 5.Unidad de Enfermedades InfecciosasHospital Universitario Virgen de la VictoriaMalagaSpain
  6. 6.Unidad de Enfermedades InfecciosasHospital General Universitario de AlicanteAlicanteSpain